Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Regulatory

NervGen Pharma Begins Trading on Nasdaq Today

By The Northwire Desk — AI Analysis Jan 08, 2026 · 06:30 NGEN · 7.82 Nervgen Pharma Corp.
NGEN · Price

Executive Summary

  • NervGen Pharma Corp.’s common shares have been approved for listing on Nasdaq and will begin trading under the ticker “NGEN” on the same day.
  • The Nasdaq listing follows recent positive Phase 1b/2a CONNECT SCI study data, positioning the company for late‑stage development of its lead candidate NVG‑291.
  • Management expects the listing to enhance visibility, liquidity, and broaden the shareholder base, supporting continued clinical advancement and potential future financing.

Key Details

  • Nasdaq Listing Approval: NervGen’s common shares are now listed on Nasdaq (symbol “NGEN”) as of Jan 8 2026.
  • Clinical Milestone Reference: The announcement references expanded Phase 1b/2a CONNECT SCI data released 24 Nov 2025, showing durable functional improvements in chronic spinal‑cord injury patients.
  • Regulatory Pathway Updates: FDA Type C meeting (Sept 2025) confirmed multiple approval pathways; an End‑of‑Phase 2 meeting is scheduled for early 2026 to align on development and registration strategy for NVG‑291.
  • Strategic Impact Statement: CEO Adam Rogers highlighted that Nasdaq listing will improve market visibility, liquidity, and diversify the shareholder base, supporting long‑term value creation as the company advances toward a potential first‑in‑class pharmacologic therapy for SCI.
  • Future Clinical Plans: Ongoing enrollment of sub‑acute SCI patients in the CONNECT study; preparation underway for a Phase 3 trial in chronic SCI.

Notable Quotes

“A listing on Nasdaq marks a defining moment in NervGen’s evolution… we believe this listing will enhance visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately drive long‑term shareholder value…” – Adam Rogers, MD, Interim CEO, NervGen Pharma.

Read the original news release →

More from Nervgen Pharma Corp.

Apr 07, 2026 · 07:30

FDA aligns on Phase 3 design, clearing the path for NVG‑291’s registrational trial

Other Mar 31, 2026 · 07:45

Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

Earnings Mar 12, 2026 · 16:15

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Financings Feb 09, 2026 · 07:00

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Other Nov 24, 2025 · 07:06

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Earnings Nov 24, 2025 · 07:02

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Other